Cache Advisors LLC Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Cache Advisors LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.9% during the third quarter, Holdings Channel reports. The firm owned 6,300 shares of the biopharmaceutical company’s stock after selling 2,316 shares during the period. Regeneron Pharmaceuticals makes up about 0.6% of Cache Advisors LLC’s holdings, making the stock its 21st biggest holding. Cache Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $3,542,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in REGN. Brighton Jones LLC raised its holdings in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $226,000. Oppenheimer Asset Management Inc. increased its position in Regeneron Pharmaceuticals by 32.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 2,608 shares of the biopharmaceutical company’s stock worth $1,369,000 after purchasing an additional 643 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $467,000. Finally, World Investment Advisors lifted its position in Regeneron Pharmaceuticals by 51.7% during the second quarter. World Investment Advisors now owns 549 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 187 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $781.67 on Friday. The firm has a 50-day moving average of $771.59 and a two-hundred day moving average of $681.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The stock has a market cap of $82.64 billion, a P/E ratio of 18.81, a PEG ratio of 2.10 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $12.07 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be paid a dividend of $0.94 per share. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Wall Street Analyst Weigh In

REGN has been the subject of several recent research reports. Canaccord Genuity Group increased their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. UBS Group raised their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Oppenheimer restated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Finally, Cantor Fitzgerald increased their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $793.81.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares of the company’s stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 5,274 shares of company stock valued at $4,142,738. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: U.S. FDA approval (announced Feb. 24) expanding Dupixent’s indication to include allergic fungal rhinosinusitis — adds a new labeled population and supports future revenue growth. Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Positive Sentiment: European Medicines Agency recommended Dupixent for approval to treat chronic spontaneous urticaria (CSU) in children aged 2–11 — if approved, this would be the first targeted EU therapy for that pediatric group, extending Dupixent’s addressable market. Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
• Positive Sentiment: Analyst sentiment improved with Wall Street Zen moving REGN to a Buy rating — upgrades can spur additional investor interest and short-term flows. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Wall Street Zen
• Positive Sentiment: Media/analyst pieces and hedge-fund screens continue to highlight Regeneron as a top gene-therapy/big-pharma pick, reinforcing investor narratives around its pipeline and R&D capabilities. Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Positive Sentiment: Dupixent sales momentum remains a core bull case — recent analysis notes ~22.8% YoY growth for Dupixent in Q4 and continued contribution to Regeneron’s top-line strength. Why Dupixent Keeps Regeneron A Top Big Pharma Pick
• Neutral Sentiment: Coverage notes REGN has lagged the Nasdaq over the past year — a reminder of relative performance risk even amid positive fundamental catalysts. Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.